# Ferrokin Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ferrokin-biosciences

- Industry: Biotechnology
- Headquarters: San Carlos, US
- Website: www.ferrokin.com
- Total disclosed funding: $27M
- Latest round: Series B (Jun 9, 2010)
- Investors on record: 5

## About

Ferrokin Biosciences Inc is a biotechnology company focused on developing innovative therapies for iron overload diseases, leveraging advanced drug delivery systems and targeting strategies to enhance treatment outcomes.Ferrokin Biosciences Inc specializes in the development of therapies aimed at treating iron overload conditions. Founded in San Carlos, US, the company has navigated a significant change in strategy, leading to its acquisition by Shire PLC in March 2012 for USD 325 mn, which included an upfront payment of USD 100 mn. The firm has engaged in a total of 6 deals, with the latest deal finalized on March 15, 2012. The company operates without any known subsidiaries or parent companies.Ferrokin Biosciences Inc concentrates on the research and development of therapies specifically designed to address iron overload disorders. Their product pipeline includes innovative treatments that utilize advanced drug delivery systems, enhancing the efficacy and safety of iron chelation therapy. These therapies are primarily targeted at patients suffering from conditions like hereditary hemochromatosis and thalassemia, showcasing the company's commitment to improving patient outcomes through scientific advancements.Ferrokin Biosciences Inc generates revenue through the commercialization of its therapeutics for iron overload diseases. The company's focus is on direct sales from their product offerings, supplemented by partnerships with healthcare providers and institutions that facilitate broader access to their therapies. Specific pricing details for their products are not publicly disclosed, but the firm positions its offerings competitively within the biopharmaceutical market.Ferrokin Biosciences Inc is focused on expanding its product line with new therapies designed to improve the management of iron overload disorders, with planned launches in the next few years. The company aims to increase its market presence, particularly in the US and European regions, seeking to establish a foothold in additional international markets by 2025. The recent acquisition by Shire PLC will provide the necessary resources to support these strategic growth initiatives and further enhance their research capabilities.

## Funding rounds

- Series B, Jun 9, 2010, $12M — Burrill & Company, HealthCap, Clarus Ventures, MP Healthcare Venture Management
- Series A, Dec 5, 2008, $6.6M — Burrill & Company, Clarus Ventures, Celgene
- Series A, Nov 5, 2008, $8.4M — Burrill & Company, Clarus Ventures, Celgene

## Investors

- Burrill & Company (https://capitalatlas.ai/funds/burrill-company) — Series A, Series B
- Clarus Ventures (https://capitalatlas.ai/funds/clarus-ventures) — Series A, Series B
- Celgene — Series A
- HealthCap — Series B
- MP Healthcare Venture Management (https://capitalatlas.ai/funds/mp-healthcare-venture-management) — Series B